Evidence
Int J Mol Sci. 2023 May 3;24(9):8203. doi: 10.3390/ijms24098203.
ABSTRACT
Chronic liver disease (CLD) has emerged as a leading cause of human deaths. It caused 1.32 million deaths in 2017, which affected men more than women by a two-to-one ratio. There are various causes of CLD, including obesity, excessive alcohol consumption, and viral infection. Among them, non-alcoholic fatty liver disease (NAFLD), one of obesity-induced liver diseases, is the major cause, representing the cause of more than 50% of cases. Fucoxanthin, a carotenoid mainly found in brown seaweed, exhibits various biological activities against NAFLD. Its role in NAFLD appears in several mechanisms, such as inducing thermogenesis in mitochondrial homeostasis, altering lipid metabolism, and promoting anti-inflammatory and anti-oxidant activities. The corresponding altered signaling pathways are the β3-adorenarine receptor (β3Ad), proliferator-activated receptor gamma coactivator (PGC-1), adenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), sterol regulatory element binding protein (SREBP), nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), protein kinase B (AKT), SMAD2/3, and P13K/Akt pathways. Fucoxanthin also exhibits anti-fibrogenic activity that prevents non-alcoholic steatohepatitis (NASH) development.
PMID:37175909 | DOI:10.3390/ijms24098203
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
🌐 90 Days
VR Related Evidence Matrix
- Role of prostaglandin E2 and its receptors in chronic liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Role of the angiopoietin-like protein family in the progression of NAFLD
- The gut-liver axis in fatty liver disease: role played by natural products
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- Sex differences in mortality and liver-related events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- The association between non-alcoholic fatty liver disease and urinary incontinence among adult females in the United States
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- COVID-19 in Individuals with Chronic Liver Diseases
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- Nonalcoholic Fatty Liver Disease and Ethnicity: Lessons Learned from the Arab Population in Israel
- Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Exploring Bile-Acid Changes and Microflora Profiles in Chicken Fatty Liver Disease Model
- Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017-2018
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Chronic exposure to ambient air pollution and the risk of non-alcoholic fatty liver disease: A cross-sectional study in Taiwan and Hong Kong
- Pomegranate supplementation alleviates dyslipidemia and the onset of non-alcoholic fatty liver disease in Wistar rats by shifting microbiota and producing urolithin-like microbial metabolites
- Association between sleep duration and a new onset of nonalcoholic fatty liver disease
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics
- The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants
- A study on the treatment effects of Crataegus pinnatifida polysaccharide on non-alcoholic fatty liver in mice by modulating gut microbiota
- Bacteroides fragilis aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota
- Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease
- Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- The Impact of Non-alcohol Fatty Liver Disease on Bone Mineral Density is Mediated by Sclerostin by Mendelian Randomization Study
- Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil
- Correlation of Grades of Non-alcoholic Fatty Liver on Ultrasound With Blood Parameters
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease
- Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
Evidence Blueprint
The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
🌐 365 Days
VR Related Evidence Matrix
- Occult liver disease: a multinational perspective
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Liver health and the interplay between obesity, alcohol and bariatric surgery
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Sleep patterns, genetic predisposition, and risk of chronic liver disease: A prospective study of 408,560 UK Biobank participants
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Corrected and republished from: Metabolic associated liver disease
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- The Role of Vitamin D in Obese Children with Non-Alcoholic Fatty Liver Disease and Associated Metabolic Syndrome
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Reduced Lipopolysaccharide-Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity
- Impact of prior HBV, HAV, and HEV infection on non-alcoholic fatty liver disease
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- The Role of Platelets in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
- Fructose Aggravates Copper-deficiency-induced Non-alcoholic Fatty Liver Disease
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population
- Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Identification and validation of cuproptosis-related molecular clusters in non-alcoholic fatty liver disease
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Association of 24 h Behavior Rhythm with Non-Alcoholic Fatty Liver Disease among American Adults with Overweight/Obesity
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- The gut-liver axis in fatty liver disease: role played by natural products
- Review of paediatric obesity and non-alcoholic fatty liver disease-A focus on emerging non-pharmacologic treatment strategies
- The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- A High-Fat Diet Increases the Characteristics of Gut Microbial Composition and the Intestinal Damage Associated with Non-Alcoholic Fatty Liver Disease
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Mass Spectrometry Reveals that Oxysterols are Secreted from Non-Alcoholic Fatty Liver Disease Induced Organoids
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- The Association between Liver Enzymes and Mortality Stratified by Non-Alcoholic Fatty Liver Disease: An Analysis of NHANES III
- The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era?
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Fatty liver disease's renaming impacts on drug clinical trials
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease